[HTML][HTML] The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications

P Economopoulou, C Perisanidis… - Annals of …, 2016 - ncbi.nlm.nih.gov
Head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, with low
survival rates for advanced stage tumors and minimal improvement in survival trends …

Therapeutic vaccines for HPV-associated malignancies

C Smalley Rumfield, N Roller, ST Pellom… - ImmunoTargets and …, 2020 - Taylor & Francis
Human papillomavirus (HPV)-related malignancies are responsible for almost all cases of
cervical cancer in women, and over 50% of all cases of head and neck carcinoma …

Update on head and neck cancer: current knowledge on epidemiology, risk factors, molecular features and novel therapies

F Pezzuto, L Buonaguro, F Caponigro, F Ionna… - Oncology, 2015 - karger.com
Tobacco use and alcohol consumption are the main risk factors associated with head and
neck squamous cell carcinoma (SCC) development due to their cytotoxic and mutagenic …

Head and neck squamous cell carcinoma: risk factors, molecular alterations, immunology and peptide vaccines

Z Sun, X Sun, Z Chen, J Du, Y Wu - International Journal of Peptide …, 2022 - Springer
Head and neck squamous cell carcinoma (HNSCC) arises from the epithelial lining of the
oral cavity, hypopharynx, oropharynx, and larynx. There are several potential risk factors that …

[HTML][HTML] An updated overview of HPV-associated head and neck carcinomas

A Zaravinos - Oncotarget, 2014 - ncbi.nlm.nih.gov
Human papilloma virus (HPV)-associated head and neck carcinoma is quite heterogeneous
and most of the tumors arise in the oral cavity, oropharynx, hypopharynx and larynx. HPV …

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and …

AP Rapoport, NA Aqui, EA Stadtmauer, DT Vogl… - Clinical cancer …, 2014 - AACR
Purpose: Myeloma-directed cellular immune responses after autologous stem cell
transplantation (ASCT) may reduce relapse rates. We studied whether coinjecting the TLR-3 …

HNSCC: tumour antigens and their targeting by immunotherapy

A von Witzleben, C Wang, S Laban, N Savelyeva… - Cells, 2020 - mdpi.com
Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of
malignant tumours typically caused by alcohol and tobacco consumption, although an …

Promising systemic immunotherapies in head and neck squamous cell carcinoma

N Gildener-Leapman, RL Ferris, JE Bauman - Oral oncology, 2013 - Elsevier
Patients with head and neck squamous cell carcinoma (HNSCC) demonstrate poor survival
and significant treatment morbidity with standard therapy. The immune profile in HNSCC …

Personalized cancer vaccination in head and neck cancer

H Shibata, L Zhou, N Xu, AM Egloff… - Cancer …, 2021 - Wiley Online Library
Cancer is characterized by an accumulation of somatic mutations that represent a source of
neoantigens for targeting by antigen‐specific T cells. Head and neck squamous cell …

Vaccine-based immunotherapy for head and neck cancers

S Beyaert, JP Machiels, S Schmitz - Cancers, 2021 - mdpi.com
Simple Summary Therapeutic vaccines are given to patients with cancer, as opposed to
prophylactic vaccines given to a healthy population. The challenge for therapeutic …